Advice
in the absence of a submission from the holder of the marketing authorisation:
aflibercept (Eylea®) is not recommended for use within NHSScotland.
Indication under review: in preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice625KB (PDF)
Medicine details
- Medicine name:
- aflibercept (Eylea)
- SMC ID:
- SMC2612
- Indication:
In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.
- Pharmaceutical company
- Bayer Plc
- BNF chapter
- Eye
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 August 2023